Cart (0 Items)
Your cart is currently empty.
View ProductsIt looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
| Size | 100ug, 1MG |
|---|---|
| Isotype | VH-C-kappa-CH2-CH3_V-lambda-CH1_H-GAMMA-1_L-kappa |
| Brand | ProteoGenix |
| Product type | Primary Antibodies |
| Clonality | Monoclonal Antibody |
| Expression system | Mammalian cells |
| Applications | Elisa, WB |
| Product name | Vanucizumab Biosimilar - Anti-ANGPT2, VEGFA, mAb - Research Grade |
|---|---|
| Source | CAS 1448221-05-3 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | Vanucizumab,RG-7221,RG7221,RO5520985,ANGPT2, VEGFA, ,anti-ANGPT2, VEGFA, |
| Reference | PX-TA1355 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | VH-C-kappa-CH2-CH3_V-lambda-CH1_H-GAMMA-1_L-kappa |
| Clonality | Monoclonal Antibody |
Vanucizumab has been investigated for the treatment of Colorectal Cancer and Advanced/Metastatic Solid Tumors.
Immobilized Human ANGPT2-Ang2 recombinant protein (cat. No. PX-P6245) at 0.5µg/mL (100µL/well) can bind Vanucizumab Biosimilar - Anti-ANGPT2, VEGFA, mAb (cat. No. PX-TA1355) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 105.6M.
Related products
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.